AFC-5278

Affectis is developing AFC-5278, an oral non-CNS penetrant P2X7 antagonist for the treatment of osteoporosis and related diseases.

The human skeleton undergoes a constant remodelling where old bone tissue is broken down in a process called bone resorption in order to be replaced by new bone tissue. Bone resorption is carried out by specialised cells called osteoclasts. Recent studies suggest that P2X7 controls certain aspects of osteoclast function. Elevated osteoclast activity results in progressive bone loss leading to osteoporosis.

Inhibition of P2X7 by AFC-5278 aims to reduce osteoclast activity, prevent bone loss and offer a new therapeutic approach for the treatment of osteoporosis.